Ain Shams Engineering Journal · مجلد 17 (5) · 104098-104098
The rapid growth of cities demands sophisticated decision support systems capable of simultaneously tackling social, economic, and environmental issues in urban planning. This research introduces a comprehensive decision-making framework that integrates machine learning to optimize urban infrastructure development. To improve the reliability of the analysis, recursive feature elimination paired with random forest (RF-RFE) is utilized to pinpoint the most critical factors, ensuring that the decision process emphasizes the features that matter most. To handle uncertainty and vagueness in expert evaluations, picture fuzzy sets are implemented, allowing a nuanced expression of hesitation, while the entropy method is employed to objectively determine the weights of social, economic, and environmental criteria, thereby reducing subjective influence. The evaluation based on the approach of relative utility and nonlinear standardization (ERUNS) is employed to rank urban planning alternatives, capturing the nonlinear interactions among criteria. This framework provides a comprehensive, data-driven decision support tool for urban planners and policymakers to address the intricate and dynamic challenges of modern urbanization.
picture fuzzy setsmulti-criteria decision makingurban planningdecision support system
Neurodegenerative disorders such as Parkinson’s disease are closely associated with dysregulated activity of monoamine oxidase-B (MAO-B), which leads to dopamine depletion and oxidative stress. Despite the availability of numerous monoamine oxidase (MAO) inhibitors on the market, their irreversibility and associated side effects necessitate the development of more effective and reversible MAO-B inhibitors. In this study, a series of twenty-one indole-based derivatives (PSH1 - PSH21) , collectively designated as PSH , was synthesised and evaluated for inhibitory activity against MAO isoforms. Most synthesised compounds showed higher inhibitory activity toward MAO-B than MAO-A, indicating selectivity for MAO-B. Among the PSH derivatives, PSH18 exhibited the most potent MAO-B inhibitory activity (IC 50 = 0.95 ± 0.02 µM), followed by PSH6 ( IC 50 = 1.79 ± 0.40 µM) and PSH2 (IC 50 = 1.96 ± 0.08 µM). Compound PSH18 showed the highest selectivity index value of 42.11, followed by PSH6 (22.35) and PSH2 (20.41). Additionally, PSH18 was confirmed to be a competitive and reversible inhibitor of MAO-B with an inhibition constant value of 0.89 ± 0.035 µM. Notably, PSH18 exhibited good permeability across the blood–brain barrier in parallel artificial membrane permeability assay experiments, along with acceptable absorption, distribution, metabolism, excretion, and toxicity parameters predicted through in silico modelling, suggesting its potential as a central nervous system-targeted molecule. Molecular docking and a 200 ns molecular dynamics simulation demonstrated stable binding of the ligand to the MAO-B active-site pocket, driven by hydrophobic and π–π stacking interactions with key amino acid residues lining the aromatic cage. Moreover, the calculated binding energy indicated strong ligand–protein interactions. Overall, these results indicate that the PSH scaffold could serve as a promising lead structure for the development of potent and selective MAO-B inhibitors. These compounds may have therapeutic potential for the treatment of neurodegenerative diseases.
monoamine oxidase B inhibitorsParkinson's diseaseblood-brain barrier permeabilityADME prediction
The increasing complexity and sophistication of cyber threats have heightened the need for robust security mechanisms throughout the Software Development Lifecycle (SDLC). Traditional security methods have proven insufficient in addressing evolving risks, prompting the exploration of advanced technologies such as Artificial Intelligence (AI). However, integrating AI into SDLC raises challenges related to human-AI collaboration, trust, and alignment. This paper aims to explore the synergistic collaboration between Human Agentic and AI agents to enhance the security of SDLC. By integrating human expertise with AI capabilities, the study investigates how this collaboration can address existing security gaps and improve threat detection, vulnerability management, and secure code development. A qualitative approach is employed, reviewing existing literature on Human-Agentic AI frameworks, AI-driven security models, and their application in SDLC security. We also propose a conceptual framework for Human Agentic-AI collaboration in SDLC security, encompassing AI’s role in automated threat detection, vulnerability scanning, and model optimization, alongside human agents’ roles in decision-making, risk evaluation, and response validation. The proposed framework demonstrates that combining human intuition with AI’s computational power significantly enhances the security posture of SDLC processes. AI’s ability to quickly process and analyze large datasets complements human agents’ contextual understanding, leading to more effective identification of vulnerabilities and proactive security measures. The collaboration results in improved threat mitigation strategies, faster response times, and more reliable secure code deployment. The integration of Human Agentic-AI collaboration offers promising potential in enhancing SDLC security. The synergistic approach bridges the limitations of traditional methods and AI systems, offering a more dynamic and adaptable security solution. Future research should focus on optimizing human-AI interfaces and addressing trust and transparency challenges to further strengthen SDLC security.
International Journal of Polymeric Materials · مجلد 75 (8) · 835-858
Folate-conjugated chitosan nanoparticles represent a promising advancement in targeted drug delivery, offering enhanced specificity, biocompatibility, and controlled release profiles. Chitosan, a versatile biopolymer, provides a stable platform for nanoparticle synthesis, while folate conjugation enables selective targeting of folate receptors, which are overexpressed in various cancers and inflammatory diseases. This review explores the structural and functional properties of chitosan, mechanisms of folate receptor-mediated endocytosis, and innovative strategies for nanoparticle synthesis and functionalization. The review entails key formulation techniques, including nanoprecipitation, ionic gelation, and spray drying, alongside characterization methods essential for optimizing therapeutic efficacy. The biomedical applications of Folate-conjugated chitosan nanoparticles are highlighted in cancer therapy, gene delivery, and anti-inflammatory treatments, with an emphasis on emerging trends such as CRISPR-based targeting and dual-ligand strategies. This review critically examines the existing challenges and explores future directions, highlighting the promising role of folate-conjugated chitosan nanoparticles in the evolution of precision medicine.
targeted drug deliveryfolate receptorreceptor-mediated endocytosisnanoprecipitation
Polynucleotides (PNs) and polydeoxyribonucleotides (PDRNs) are increasingly used in regenerative dermatology; however, randomized evidence across skin rejuvenation, scar prevention, and wound healing has not been comprehensively synthesized. This systematic review evaluated randomized clinical trials investigating PN- and PDRN-based interventions in these indications. PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched through January 2026. Seven randomized trials involving 183 participants met the inclusion criteria. Four studies evaluated skin rejuvenation, one postoperative scar prevention, and two wound-healing applications. Across studies, PN and PDRN therapies improved wrinkle-related outcomes, scar quality, wound-healing metrics, and patient-reported satisfaction. The most consistent benefits were observed in wound-healing settings, where PDRN accelerated re-epithelialization and shortened healing time compared with controls. No serious treatment-related adverse events were reported. Although findings support the regenerative potential of PN- and PDRN-based therapies across multiple dermatologic applications, the evidence base remains limited by small sample sizes, heterogeneous treatment protocols, and variable outcome measures. Larger, adequately powered randomized trials are needed to establish optimal clinical indications and treatment strategies.
The advent of CRISPR‒Cas technology has revolutionized genome editing by providing unprecedented precision, efficiency, and versatility in genetic manipulation. This revolutionary system originated from bacterial adaptive immunity. It allows the programmed modification of DNA sequences in a highly specific way, as long as the desired modification site contains an enzyme-compatible protospacer adjacent motif (PAM) sequence. Recent innovations with CRISPR‒Cas systems have focused on optimizing delivery methods, addressing challenges and expanding their therapeutic applications. Delivery approaches, including viral vectors, lipid nanoparticles, and other nonviral vectors, have been improved to increase target specificity while minimizing off-target effects, ensuring safe and efficient In Vivo genome editing. The applications of CRISPR‒Cas technology include the correction of genetic disorders, engineering of immune cells for cancer therapy, and combating viral infections. However, significant challenges in the form of unintended edits, immune responses, and delivery to specific tissues or organs remain formidable barriers to clinical translation. New CRISPR variants, such as base editing, prime editing, and epigenome editing, provide solutions to improve accuracy and broaden intervention. This review covers recent progress in various CRISPR delivery methodologies, discusses broadening therapeutic applications, highlights ongoing challenges, and describes the future trajectory of this disruptive technology.